CRISPR Therapeutics AG

NASDAQ:CRSP   1:12:16 PM EDT
173.50
-7.74 (-4.27%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)12.82B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$2.36 Million
Adjusted EPS-$1.27
See more estimates
10-Day MA$185.07
50-Day MA$153.09
200-Day MA$98.02
See more pivots

CRISPR Therapeutics AG Stock, NASDAQ:CRSP

BAARERSTRASSE 14, ZUG, SWITZERLAND CH-6300
Switzerland
Phone: 6173154600
Number of Employees: 188
www.crisprtx.com

Description

CRISPR Therapeutics AG focuses on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. The CRISPR/Cas9 technology allows for changes to genomic DNA. The company has strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in other diseases. It operates in Switzerland, the United States, and the United Kingdom. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.